Ocumetics Announces Positive Results from First-in-Human Clinical Study
Calgary, Alberta — February 3, 2026 — Leads & Copy —
Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) announced positive three-month postoperative results from Group 1 patients in its first-in-human (FIH) clinical study of the Ocumetics Accommodating Intraocular Lens. The results validate the Company’s core technology and represent a key clinical de-risking milestone as Ocumetics advances toward subsequent study phases.
The Group 1 data met or exceeded all predefined internal benchmarks for safety, lens delivery, and foundational distance visual performance, successfully achieving the primary objectives required to progress the clinical program.
According to Dean Burns, President and CEO of Ocumetics, the first-in-human results are exactly what the company was aiming to demonstrate at this stage: safe implantation, reliable delivery, and strong visual outcomes. Burns added that following a detailed review of the data with Dr. Raphael Vasquez, the primary surgeon, he remains 100% confident in the accommodating intraocular lens technology, and based on this success, the company has initiated planning for Group 2 surgeries.
Group 1 patients entered the study with severe visual impairment, with some presenting uncorrected preoperative acuities as poor as 20/250, levels consistent with legal blindness. Post-implantation outcomes underscore both the clinical effectiveness and real-world impact of the Ocumetics Lens.
Dr. Rafael Vázquez MD, principal investigator of the Ocumetics first-in-human trial, said that all patient outcomes have met safety expectations, and the profile of the patients he selected had poor vision, and as a result of the implantations, they have experienced a truly life changing event. He added that from being classified legally blind, his patients can now read, enjoy everyday life activities, and drive, and the impact on their independence and sense of freedom has been remarkable.
The results from Group 1 can be summarized as:
• Safety profile met expectations
• Visual acuity outcomes met and exceeded expectations
• Lens delivery system met expectations
Ocumetics continues to apply its rapid “win-learn” R&D approach, incorporating surgeon feedback in real time to further optimize performance. Based on insights from Group 1, the Company has already implemented refinements to the lens delivery mechanism and initiated multiple lens optimization initiatives aimed at enhancing outcomes in Group 2.
Manufacturing and testing of optimized lens designs are currently underway. Group 2 surgeries are expected to be scheduled following completion of final lens testing and validation.
Burns concluded that the Group 1 results clearly demonstrated and confirmed the viability of the accommodating intraocular lens technology, this milestone materially strengthens the clinical foundation and positions Ocumetics to build momentum as they advance into Group 2, and that they are excited to continue executing on their clinical and development roadmap.
Ocumetics is in the first-in-human early feasibility study phase of a technology for the ophthalmic industry and has developed an intraocular lens that fits within the natural lens compartment of the eye, potentially to eliminate the need for corrective lenses. It is designed to allow the eye’s natural muscle activity to shift focus from distance to near, providing clear vision at all distances without the help of glasses or contact lenses.
Ocumetics is holding a webinar on Wednesday, February 4, 2026 at 4:00 PM ET.
Source: Ocumetics Technology Corp.
Share this story:
